8-K: Mangoceuticals Explores Avian Flu Treatment in Poultry with Water-Based Solution

Mangoceuticals is researching a non-invasive, water-based solution to combat avian flu in the poultry industry.

Summary

• Mangoceuticals is researching a potential treatment for Avian Flu in the poultry industry.
• The company is using a non-invasive, non-pharmaceutical water-based solution.
• They have engaged Vipragen Biosciences to conduct independent efficacy studies.
• The studies are based on patented respiratory illness prevention technology acquired from IntraMont Technologies, Inc.
• Phase I animal studies showed significant efficacy in reducing lung viral load, and Phase II studies are underway.
• The company is assessing the feasibility of a drinking water-based application for poultry.
• The solution uses Generally Recognized as Safe (GRAS) ingredients.
• Since 2022, over 148 million birds have been culled in the United States due to avian flu.
• The national average price of eggs hit $4.15 per dozen as of December 2024, with forecasts predicting an additional 20% increase in 2025.
• The global poultry market is projected to reach $375.41 billion by 2030.

Sentiment

Score: 6

Explanation: The announcement is cautiously optimistic, highlighting the potential of the new technology while acknowledging the risks and uncertainties involved in research and development. The focus on a significant problem (avian flu) and a potentially innovative solution contributes to a moderately positive sentiment.

Positives

• The water-based solution is non-invasive and non-pharmaceutical.
• The solution uses Generally Recognized as Safe (GRAS) ingredients.
• Phase I animal studies have shown significant efficacy in reducing lung viral load.
• The solution could potentially reduce the financial strain on farmers dealing with avian flu outbreaks.
• The solution could be a proactive, scalable, and easily deployable solution to help prevent infections before they spread.

Risks

• The study is still in progress, and there are no assurances that the solution will be effective.
• Forward-looking statements are subject to risks, uncertainties, and other factors that could cause actual results to differ materially.
• The company's products have not been approved by the U.S. Food and Drug Administration (FDA).
• The company faces competition from other companies in the health and wellness market.
• The company's ability to raise funding and generate revenues to support its operations is uncertain.

Future Outlook

The company anticipates sharing final study results upon completion of the study, while ensuring proper intellectual property protections ahead of commercialization.

Management Comments

• Jacob Cohen, Founder and CEO of Mangoceuticals, stated that the company's initial animal study research has indicated significant efficacy in reducing viral loads in respiratory illnesses.
• Jacob Cohen believes that if proven effective in studies, this could be a simple, everyday solution that fits seamlessly into existing poultry farming practices while reducing the financial strain on farmers.

Industry Context

The announcement addresses the ongoing avian flu outbreak, which has significantly impacted the poultry industry, leading to culling of birds, disrupted supply chains, and increased consumer prices. Mangoceuticals is positioning itself to provide a solution to this problem.

Comparison to Industry Standards

• Traditional approaches to combating avian flu rely on synthetic vaccines or pharmaceutical treatments, while Mangoceuticals' antiviral technology leverages Generally Recognized as Safe (GRAS) ingredients added to poultry drinking water.
• The press release does not provide specific comparisons to other companies or projects in terms of efficacy or cost-effectiveness, but it emphasizes the potential for a simple, compliant, and non-pharmaceutical approach.

Stakeholder Impact

• Shareholders: Potential for increased value if the technology is successful.
• Poultry farmers: Potential for a cost-effective solution to prevent avian flu.
• Consumers: Potential for stabilized egg and poultry prices.
• Global health: Potential to prevent future pandemics.

Next Steps

• Conducting Phase II animal studies.
• Testing the efficacy of the solution when administered through drinking water.
• Evaluating any necessary modifications to optimize its effectiveness in preventing avian flu infections among poultry populations.
• Sharing final study results upon completion of the study.
• Ensuring proper intellectual property protections ahead of commercialization.

Key Dates

Keywords

avian flu, poultry, antiviral, Mangoceuticals, water-based solution, respiratory illness, Vipragen Biosciences, IntraMont Technologies, GRAS ingredients